Synaptogenix to Present at the Cell Symposium

NEW YORK, May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will have a presentation at the Cell Symposium conference in Sitges, Spain on Tuesday, May 17^th. The title of the poster is "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." 

Read more at prnewswire.com